Seoul Pharma Co. Ltd - Asset Resilience Ratio

Latest as of March 2025: 9.30%

Seoul Pharma Co. Ltd (018680) has an Asset Resilience Ratio of 9.30% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Seoul Pharma Co. Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩6.64 Billion
≈ $4.50 Million USD Cash + Short-term Investments

Total Assets

₩71.39 Billion
≈ $48.38 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2024)

This chart shows how Seoul Pharma Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 018680 asset base.

Liquid Assets Composition Over Time

This chart breaks down Seoul Pharma Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 018680 long-term investments to assets to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩5.66 Billion 7.93%
Short-term Investments ₩979.26 Million 1.37%
Total Liquid Assets ₩6.64 Billion 9.30%

Asset Resilience Insights

  • Limited Liquidity: Seoul Pharma Co. Ltd maintains only 9.30% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Seoul Pharma Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Seoul Pharma Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Yunnan Baiyao Group Co Ltd
SHE:000538
Drug Manufacturers - Specialty & Generic 8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Jiuzhitang Co Ltd
SHE:000989
Drug Manufacturers - Specialty & Generic 7.86%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Seoul Pharma Co. Ltd (2012–2024)

The table below shows the annual Asset Resilience Ratio data for Seoul Pharma Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 10.53% ₩7.54 Billion
≈ $5.11 Million
₩71.62 Billion
≈ $48.54 Million
-4.74pp
2023-12-31 15.27% ₩9.66 Billion
≈ $6.55 Million
₩63.31 Billion
≈ $42.90 Million
-3.52pp
2022-12-31 18.79% ₩11.73 Billion
≈ $7.95 Million
₩62.43 Billion
≈ $42.31 Million
-3.41pp
2021-12-31 22.20% ₩13.82 Billion
≈ $9.37 Million
₩62.25 Billion
≈ $42.19 Million
-0.94pp
2020-12-31 23.14% ₩15.06 Billion
≈ $10.21 Million
₩65.09 Billion
≈ $44.11 Million
+12.33pp
2019-12-31 10.81% ₩7.67 Billion
≈ $5.19 Million
₩70.89 Billion
≈ $48.04 Million
+1.72pp
2018-12-31 9.09% ₩8.23 Billion
≈ $5.58 Million
₩90.57 Billion
≈ $61.38 Million
+4.00pp
2017-12-31 5.09% ₩4.43 Billion
≈ $3.00 Million
₩86.93 Billion
≈ $58.91 Million
-5.35pp
2016-12-31 10.45% ₩9.67 Billion
≈ $6.55 Million
₩92.54 Billion
≈ $62.71 Million
+10.19pp
2012-12-31 0.25% ₩153.00 Million
≈ $103.69K
₩60.68 Billion
≈ $41.12 Million
--
pp = percentage points

About Seoul Pharma Co. Ltd

KQ:018680 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$15.52 Million
₩22.90 Billion KRW
Market Cap Rank
#25988 Global
#1949 in Korea
Share Price
₩1964.00
Change (1 day)
-0.51%
52-Week Range
₩1932.00 - ₩3230.00
All Time High
₩17976.69
About

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms o… Read more